Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer
Anlotinib demonstrated mild efficacy in the treatment of recurrent EOC, whether employed as monotherapy, chemotherapy-combined therapy, or maintenance therapy. The safety profile was proven manageable and well-tolerated, suggesting that anlotinib may emerge as a viable and novel treatment option for recurrent EOC.
Authors
- Kaiyun Qin
- Xin Zhou (ORCID: https://orcid.org/0000-0001-9281-3612)
- Yu Yu
- Zhengmao Zhang (ORCID: https://orcid.org/0000-0003-4461-4154)
- Ying He
- A. Zhai
Institutions
- Hebei Medical University (CN)
- Hebei North University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hebei General Hospital (CN)
- Baoding People's Hospital (CN)
- Baoding No.1 Central Hospital
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s12672-024-01267-8
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.54